ES2421886T3 - Método para producción de un agente de representación de imágenes de diagnóstico por radiación - Google Patents

Método para producción de un agente de representación de imágenes de diagnóstico por radiación

Info

Publication number
ES2421886T3
ES2421886T3 ES08711095T ES08711095T ES2421886T3 ES 2421886 T3 ES2421886 T3 ES 2421886T3 ES 08711095 T ES08711095 T ES 08711095T ES 08711095 T ES08711095 T ES 08711095T ES 2421886 T3 ES2421886 T3 ES 2421886T3
Authority
ES
Spain
Prior art keywords
solution
dilution
dilution step
acid
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08711095T
Other languages
English (en)
Inventor
Daisaku Nakamura
Soichi Nakamura
Masahito Toyama
Akio Hayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Original Assignee
Nihon Medi Physics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Medi Physics Co Ltd filed Critical Nihon Medi Physics Co Ltd
Application granted granted Critical
Publication of ES2421886T3 publication Critical patent/ES2421886T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/48—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para producir un agente radiactivo de representación de imágenes de diagnóstico, quecomprende un paso de preparación de la solución que consiste en preparar una solución que contiene uncompuesto orgánico marcado con flúor radiactivo representado por la fórmula (1) siguiente: y un paso de dilución que consiste en diluir la solución que contiene el compuesto orgánico marcado con flúorradiactivo a fin de ajustar la concentración radiactiva del mismo, que comprende adicionalmente un paso de adición de ácido que consiste en añadir un ácido a la solución quecontiene el compuesto orgánico marcado con flúor radiactivo, después del paso de preparación de la solución yantes del paso de dilución, en donde el ácido se añade en el paso de adición de ácido en una cantidad suficiente para ajustar el pH de lasolución resultante del paso de dilución a 2,0-4,9 y en una cantidad correspondiente a 0,40-2,8 milimoles por 1L dela solución resultante del paso de dilución, y en donde el paso de adición de ácido comprende no sólo añadir un ácido, sino también añadir un azúcar o azúcar15alcohol en una cantidad que satisface una concentración no menor que 0,5 milimoles/L en la solución resultante delpaso de dilución, y/o, el paso de dilución comprende no sólo añadir un líquido para dilución, sino también añadir unazúcar o azúcar-alcohol en una cantidad que satisface una concentración no menor que 0,5 milimoles/L en lasolución resultante del paso de dilución.
ES08711095T 2007-02-13 2008-02-12 Método para producción de un agente de representación de imágenes de diagnóstico por radiación Active ES2421886T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007031692 2007-02-13
PCT/JP2008/052231 WO2008099800A1 (ja) 2007-02-13 2008-02-12 放射性画像診断剤の製造方法

Publications (1)

Publication Number Publication Date
ES2421886T3 true ES2421886T3 (es) 2013-09-06

Family

ID=39690029

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08711095T Active ES2421886T3 (es) 2007-02-13 2008-02-12 Método para producción de un agente de representación de imágenes de diagnóstico por radiación

Country Status (9)

Country Link
US (2) US8343459B2 (es)
EP (1) EP2119458B9 (es)
JP (1) JP5258583B2 (es)
KR (1) KR101485445B1 (es)
CN (1) CN101636183B (es)
CA (1) CA2678020C (es)
ES (1) ES2421886T3 (es)
TW (1) TWI406674B (es)
WO (1) WO2008099800A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2428415C2 (ru) 2005-11-29 2011-09-10 Нихон Меди-Физикс Ко., Лтд. Соединение-предшественник органического соединения, меченного радиоактивным галогеном
US20100056826A1 (en) * 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
PT2106808T (pt) 2006-12-21 2018-03-26 Nihon Mediphysics Co Ltd Agente de imagiologia de diagnóstico radioativo compreendendo ácido 1-amino-3-[18f]fluoro-ciclobutanocarboxílico
JP5258583B2 (ja) * 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
MX2010005122A (es) * 2007-11-07 2010-08-18 Ge Healthcare Bv Estabilizacion de radiofarmaceuticos.
KR20160030589A (ko) 2009-04-15 2016-03-18 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
AU2011351550B2 (en) * 2010-12-29 2017-02-02 Ge Healthcare Limited Eluent solution
US20130005958A1 (en) * 2011-06-30 2013-01-03 General Electric Company Devices and methods for reducing radiolysis of radioisotopes
US20130004414A1 (en) * 2011-06-30 2013-01-03 General Electric Company Devices and methods for reducing radiolysis of radioisotopes
US11534494B2 (en) 2011-12-21 2022-12-27 Ge Healthcare Limited Formulation and method of synthesis
CN109966515A (zh) * 2011-12-21 2019-07-05 通用电气健康护理有限公司 在柠檬酸盐缓冲液中的18F-Fluciclovine组合物
GB201411569D0 (en) 2014-06-30 2014-08-13 Ge Healthcare Ltd Novel formulation and method of synthesis
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
GB201214220D0 (en) * 2012-08-09 2012-09-19 Ge Healthcare Ltd Radiosynthesis
GB2561122B (en) * 2012-12-21 2019-07-17 Ge Healthcare Ltd Composition comprising [18F]-Fluciclovine
GB201305687D0 (en) 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
DE102016012552A1 (de) * 2016-10-20 2018-04-26 Carl Freudenberg Kg Dichtung und Dichtungsanordnung
EP3743115A1 (en) * 2018-01-24 2020-12-02 AC Immune SA Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727145A (en) 1986-09-22 1988-02-23 Ortho Pharmaceutical Corporation 2- Or 3- aryl substituted imidazo [1,2-a]pyridines
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US4871745A (en) 1986-09-22 1989-10-03 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo(1,2-A)pyridines and their use as antisecretory agents
US4791117A (en) 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
BR9611047A (pt) 1995-10-17 2000-03-08 Searle & Co Processo de deteção de ciclo oxigenase-2
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US6027710A (en) * 1996-09-18 2000-02-22 Nihon Medi-Physiscs Co., Ltd. Radiation-protecting agent
JP4242465B2 (ja) 1996-09-18 2009-03-25 日本メジフィジックス株式会社 放射線防護剤
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
AU759945B2 (en) 1998-08-20 2003-05-01 Regents Of The University Of California, The Methods for labeling beta-amyloid plaques and neurofibrillary tangles
JP4025468B2 (ja) 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
WO2001074813A2 (en) 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS
AU2001249679A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
US20010051632A1 (en) 2000-03-31 2001-12-13 Wenying Chai Phenyl-substituted indolizines and tetrahydroindolizines
US6514969B2 (en) 2000-08-16 2003-02-04 Boehringer Ingelheim Pharma Kg β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions
DE10040016A1 (de) 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
CZ20032597A3 (cs) 2001-02-26 2004-12-15 Bristol-Myers Squibb Pharma Company Analogy kyseliny askorbové pro metaloradiofarmaceutika
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
ATE337316T1 (de) 2001-06-21 2006-09-15 Smithkline Beecham Corp Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
CN1299777C (zh) 2001-08-27 2007-02-14 宾夕法尼亚州大学理事会 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
EP1356827A1 (en) 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
JP2006505610A (ja) 2002-11-05 2006-02-16 イヨン ベアム アプリカスィヨン エッス．アー． １８−ｆ標識放射性製剤の安定化
GB0229695D0 (en) 2002-12-20 2003-01-29 Amersham Plc Solid-phase preparation of 18F-labelled amino acids
BRPI0418328A (pt) 2003-12-31 2007-05-02 Schering Plough Ltd controle de parasitas em animais pelo uso de derivados de imidazo [1,2-b]piridazina
GB0422004D0 (en) 2004-10-05 2004-11-03 Amersham Plc Method of deprotection
AU2006250594B2 (en) * 2005-05-23 2011-06-16 Nihon Medi-Physics Co., Ltd. Novel organic compound and method for producing radioactive halogen-labeled organic compound using the same
JP5112062B2 (ja) 2005-06-14 2013-01-09 日本メジフィジックス株式会社 放射性画像診断剤
CA2612187C (en) * 2005-06-23 2013-05-07 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
PT2017258E (pt) * 2006-05-11 2012-04-12 Nihon Mediphysics Co Ltd Processo de produção de um composto orgânico marcado com flúor radioactivo
US8303935B2 (en) 2006-05-19 2012-11-06 Nihon Medi-Physics Co., Ltd. Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid
JP4273133B2 (ja) 2006-05-31 2009-06-03 キヤノン株式会社 デジタル放送受信装置、デジタル放送受信装置の制御方法、及びプログラム
US20100056826A1 (en) 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
PT2106808T (pt) * 2006-12-21 2018-03-26 Nihon Mediphysics Co Ltd Agente de imagiologia de diagnóstico radioativo compreendendo ácido 1-amino-3-[18f]fluoro-ciclobutanocarboxílico
JP5258583B2 (ja) * 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
KR20100091965A (ko) 2007-10-24 2010-08-19 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
AU2008314871A1 (en) 2007-10-26 2009-04-30 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
KR20100101577A (ko) 2007-10-30 2010-09-17 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법

Also Published As

Publication number Publication date
US8343459B2 (en) 2013-01-01
EP2119458A4 (en) 2010-03-24
EP2119458B9 (en) 2013-08-21
CA2678020C (en) 2015-03-24
KR20090111331A (ko) 2009-10-26
US20120301399A1 (en) 2012-11-29
TWI406674B (zh) 2013-09-01
JP5258583B2 (ja) 2013-08-07
US8658132B2 (en) 2014-02-25
EP2119458A1 (en) 2009-11-18
CA2678020A1 (en) 2008-08-21
CN101636183B (zh) 2014-03-19
EP2119458B1 (en) 2013-05-15
WO2008099800A1 (ja) 2008-08-21
KR101485445B1 (ko) 2015-01-22
TW200833362A (en) 2008-08-16
HK1138504A1 (en) 2010-08-27
US20100119448A1 (en) 2010-05-13
CN101636183A (zh) 2010-01-27
JPWO2008099800A1 (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
ES2421886T3 (es) Método para producción de un agente de representación de imágenes de diagnóstico por radiación
Pandey et al. Production of 89Zr via the 89Y (p, n) 89Zr reaction in aqueous solution: effect of solution composition on in-target chemistry
PE20100716A1 (es) Proceso para la sintesis de 1-bromo-3-nitro-5-trifluorometil-benceno
TW200740443A (en) Water for preparing dialysis solution, dialysis solution formed by the water, manufacture method of the dialysis solution and dialysis apparatus
CO6300860A2 (es) Proceso para preparar derivados del acido 2-amino-5-cianobenzoico
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
CO6290780A2 (es) Fluido para el tratamiento de una sola etapa de formaciones silíceas subterraneas
CO6741173A2 (es) Proceso para lixiviar óxido de cobre reemplazando ácido súlfurico por un agente orgánico lixiviante no contaminante
AR105044A1 (es) Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
WO2008105464A1 (ja) カルボン酸クロライドの製造方法
CN103484121A (zh) 常温水相法制备近红外荧光Ag2Se胶体半导体纳米晶的方法
Swallow 243. The action of γ-radiation on aqueous solutions of cysteine
BR112012030173A2 (pt) método, sistema de computador ,e, meio legível por computador não transitório
Yang et al. Recent progresses in NIR-II Luminescent bio/chemo sensors based on lanthanide nanocrystals
Licul-Kucera et al. Finding a way out? Comprehensive biotransformation study of novel fluorinated surfactants
CN104007076A (zh) 污水测汞方法
AR124508A1 (es) Mineralización de compuestos orgánicos con electrodo de diamante dopado con boro durante el proceso de extracción de radionúclidos
US20160075615A1 (en) Stabilization of Radiosynthetic Intermediates
CN102388860B (zh) 一种小型法医昆虫标本的制取方法
US10787406B2 (en) Composition containing C8F17Br and method for producing C8F17Br
ES2559654T3 (es) Procedimiento de producción continua de una dispersión acuosa de resina de poli(met)acrilato
CL2020001297A1 (es) Método para determinar la concentración de cloro libre en una torre, utilizando el cloro como base activa.
DE602005009205D1 (de) Verfahren zur Wiederverwertung eines Thallium-203-Isotops in einer Restlösung aus Thallium-201-Radioisotop
PE20090735A1 (es) Nuevo proceso para la obtencion de cloruros de acido
Tunc Dissolution kinetics of ulexite in phosphoric acid